United Therapeutics Corp., of Silver Spring, saw its bottom line plunge in 2013’s fourth quarter, reporting a net loss of $30.3 million, or 60 cents per diluted share, versus net income of $83.25 million, or $1.60 per diluted share, for the year-before period.
Revenue totaled $289 million in the 2013 quarter versus $243.8 million in the prior-year period.
Analysts surveyed by Thomson Reuters had forecast, on average, earnings of $1.51 per share on revenue of $295.43 million.
Research and development expenses more than tripled year-to-year, and selling, general and administrative expenses almost quadrupled.
United Therapeutics develops and markets treatments for unmet medical needs of patients with chronic and life-threatening conditions.